Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yoshiko Kawabe is active.

Publication


Featured researches published by Yoshiko Kawabe.


Journal of Infection | 2008

Comparison of the sensitivity and specificity of two whole blood interferon-gamma assays for M. tuberculosis infection

Nobuyuki Harada; Kazue Higuchi; Takashi Yoshiyama; Yoshiko Kawabe; Akira Fujita; Yuka Sasaki; Masahide Horiba; Satoshi Mitarai; Makoto Yonemaru; Hideo Ogata; Haruhiko Ariga; Atsuyuki Kurashima; Akihiko Wada; Mikio Takamori; Fumio Yamagishi; Kiminori Suzuki; Toru Mori; Nobukatsu Ishikawa

OBJECTIVES To compare the sensitivity and the specificity of the QuantiFERON-TB Gold (QFT-G) and QuantiFERON-TB Gold In Tube (QFT-GIT) diagnostic tests for Mycobacterium tuberculosis infection. METHODS One-hundred patients with culture and/or PCR confirmed M. tuberculosis infection and 168 volunteers with no risk factors for M. tuberculosis infection were tested to estimate sensitivity and specificity, respectively. RESULTS Analysis of data from the tuberculosis (TB) patients with valid results found the sensitivity of QFT-GIT (92.6%, 87/94) to be significantly higher than that for the QFT-G test (81.4%, 79/97; p=0.023). The specificity of both QFT-GIT and QFT-G was 98.8% (CI: 95.1%-99.8%) with 2 of the 160 low risk subjects with valid results for both tests being positive. Data analysis confirmed the manufacturers recommended test cut-off as being optimal, but identified higher sensitivity could be obtained by using a lower cut-off, with only a moderate decrease in specificity. CONCLUSIONS The QFT-GIT test had enhanced sensitivity for detection of M. tuberculosis infection over the QFT-G test, whilst maintaining equivalent high specificity. The logistic benefits of the QFT-GIT test format, as well as its higher sensitivity, should enable enhanced TB control.


Clinical Infectious Diseases | 2007

Diagnosis of Active Tuberculous Serositis by Antigen-Specific Interferon-γ Response of Cavity Fluid Cells

Haruyuki Ariga; Yoshiko Kawabe; Hideaki Nagai; Atsuyuki Kurashima; Kimihiko Masuda; Hirotoshi Matsui; Atsuhisa Tamura; Naohiro Nagayama; Shinobu Akagawa; Kazuko Machida; Akira Hebisawa; Yutsuki Nakajima; Hideki Yotsumoto; Toru Mori

BACKGROUND To develop a more accurate methodology for diagnosing active tuberculous pleurisy, as well as peritonitis and pericardits of tuberculous origin, we established an antigen-specific interferon gamma (IFN-gamma)-based assay that uses cavity fluid specimens. METHODS Over a 19-month period, 155 consecutive, nonselected patients with any cavity effusion were evaluated. Study subjects were 28 patients with bacteriologically confirmed active tuberculous serositis and 47 patients with definitive nontuberculous etiology. Culture was performed for 18 h with fluid mononuclear cells in the supernatant of the effusion together with saline or Mycobacterium tuberculosis-specific antigenic peptides, early secretory antigenic target 6 and culture filtrate protein 10. IFN-gamma concentrations in the culture supernatants were measured. RESULTS In patients with active tuberculous serositis, antigen-specific IFN-gamma responses of cavity fluid samples were significantly higher than those of nontuberculous effusion samples. Area under the receiver operating characteristic (AUROC) curve was significantly greater for cavity fluid IFN-gamma response (AUROC curve, 0.996) than for cavity fluid adenosine deaminase and whole-blood IFN-gamma responses (AUROC curve, 0.882 and 0.719, respectively; P = .037 and P < .001, respectively). Although the AUROC curve was greater for cavity fluid IFN-gamma response than for background cavity fluid IFN-gamma level (AUROC curve, 0.975), the AUROC curves were not statistically significantly different (P = .74). However, multivariate logistic regression analysis revealed that cavity fluid IFN-gamma responses were significantly associated with the diagnosis, even after adjustment for background IFN-gamma level (adjusted odds ratio, 1.21; 95% confidence interval, 1.03-1.42; P < .001). CONCLUSIONS The cavity fluid IFN-gamma assay could be a method for accurately and promptly diagnosing active tuberculous serositis.


Journal of Clinical Microbiology | 2008

Biological and Molecular Characteristics of Mycobacterium tuberculosis Clinical Isolates with Low-Level Resistance to Isoniazid in Japan

Chiyoji Abe; Ikuo Kobayashi; Satoshi Mitarai; Masako Wada; Yoshiko Kawabe; Tetsuya Takashima; Katsuhiro Suzuki; Li-Hwei Sng; Suxing Wang; Hla Hla Htay; Hideo Ogata

ABSTRACT We reevaluated the BACTEC MGIT 960 antimicrobial susceptibility testing system (MGIT 960 AST) by using 1,112 isolates of Mycobacterium tuberculosis. When the results of MGIT 960 AST were compared with that of the proportion method using Ogawa medium (Ogawa PM), discrepant results were obtained for 30 strains with isoniazid, all resistant by MGIT 960 AST but susceptible by Ogawa PM. For 93% of the strains that produced discrepant results, the MIC was 0.4 or 0.8 μg/ml, showing resistance by the proportion method using Middlebrook agar plates. Furthermore, it was also established by analyses of the katG and inhA genes that strains resistant only by MGIT 960 AST have a low level of isoniazid (INH) resistance, indicating that MGIT 960 AST is a reliable method. Ninety-six strains were resistant to 0.1 μg/ml INH by MGIT 960 AST. When they were divided into three groups, Low-S (susceptible at 0.2 μg/ml), Low-R (resistant at 0.2 μg/ml), and High-R (resistant at 1.0 μg/ml), by Ogawa PM, 43.3% of the Low-S strains had mutations in the promoter region of inhA and no mutations were detected in katG codon 315, while 61.7% of the High-R strains had katG codon 315 mutations or a gross deletion of katG. These results suggest that mutations in inhA are associated with low-level resistance to INH and katG codon 315 mutations are associated with high-level resistance to INH. In addition, the analyses demonstrated some relationship of mutations in the inhA gene with ethionamide resistance for the Low-S strains, but not for the High-R strains.


American Journal of Respiratory and Critical Care Medicine | 2004

Specific Detection of Tuberculosis Infection: An Interferon-γ–based Assay Using New Antigens

Toru Mori; Mitsunori Sakatani; Fumio Yamagishi; Tetsuya Takashima; Yoshiko Kawabe; Keiji Nagao; Eriko Shigeto; Nobuyuki Harada; Satoshi Mitarai; Masaji Okada; Katsuhiro Suzuki; Yoshikazu Inoue; Kazunari Tsuyuguchi; Yuka Sasaki; Gerald H. Mazurek; Izuo Tsuyuguchi


Medical Microbiology and Immunology | 2009

Comparison of performance in two diagnostic methods for tuberculosis infection

Kazue Higuchi; Yoshiko Kawabe; Satoshi Mitarai; Takashi Yoshiyama; Nobuyuki Harada; Toru Mori


Kekkaku(Tuberculosis) | 1999

ACTIVE PULMONARY TUBERCULOSIS IN PATIENTS WITH LUNG CANCER

Atsuhisa Tamura; Akira Hebisawa; Go Tanaka; Hideo Tatsuta; Tomomasa Tsuboi; Hideaki Nagai; Koji Hayashi; Yuzo Sagara; Yoshiko Kawabe; Shinobu Akagawa; Naohiro Nagayama; Kazuko Machida; Atsuyuki Kurashima; Koji Sato; Kanae Fukushima; Hideki Yotsumoto; Masashi Mori


Kekkaku(Tuberculosis) | 2004

LEUKOPENIA DUE TO ANTI-TUBERCULOUS CHEMOTHERAPY INCLUDING RIFAMPICIN AND ISONIAZID

Naohiro Nagayama; Yuichiro Shishido; Kimihiko Masuda; Baba M; Atsuhisa Tamura; Hideaki Nagai; Shinobu Akagawa; Yoshiko Kawabe; Kazuko Machida; Atsuyuki Kurashima; Hikotaro Komatsu; Hideki Yotsumoto


Kekkaku(Tuberculosis) | 2008

[Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].

Kaneko Y; Naohiro Nagayama; Yoshiko Kawabe; Masahiro Shimada; Junko Suzuki; Makiko Kunogi; Yoshinori Matsui; Masahiro Kawashima; Haruyuki Ariga; Oshima N; Kimihiko Masuda; Hirotoshi Matsui; Hideaki Nagai; Atsuhisa Tamura; Shinobu Akagawa; Toyoda E; Kazuko Machida; Atsuyuki Kurashima; Hideki Yotsumoto


Kekkaku(Tuberculosis) | 2003

[Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].

Yuichiro Shishido; Naohiro Nagayama; Kimihiko Masuda; Baba M; Atsuhisa Tamura; Hideaki Nagai; Shinobu Akagawa; Yoshiko Kawabe; Kazuko Machida; Atsuyuki Kurashima; Hikotaro Komatsu; Hideki Yotsumoto


Japanese Journal of Clinical Oncology | 1999

Lung Cancer in Patients Who Had Received Thoracoplasty for Pulmonary Tuberculosis

Atsuhisa Tamura; Akira Hebisawa; Koji Hayashi; Yuzo Sagara; Yoshiko Kawabe; Naohiro Nagayama; Kazuko Machida; Kanae Fukushima; Hideki Yotsumoto; Masashi Mori

Collaboration


Dive into the Yoshiko Kawabe's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hideaki Nagai

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Naohiro Nagayama

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kazuko Machida

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Shinobu Akagawa

Tokyo Medical and Dental University

View shared research outputs
Top Co-Authors

Avatar

Atsuhisa Tamura

Tokyo Medical and Dental University

View shared research outputs
Top Co-Authors

Avatar

Kimihiko Masuda

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Akira Hebisawa

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge